The biochemistry of the mystical – a psychedelics renaissance?

When the Swiss chemist synthesized and tested the psychedelic
compound LSD in the 1930s, he knew he had found a tool to explore
the human mind. Indeed, before psychedelics became illegal in the
late 1960s, a mountain of evidence had been produced, showing
potential benefits of psychedelic-assisted therapy for depression,
anxiety, and substance abuse. After a decades-long hiatus, research
on psychedelics as a treatment for psychiatric diseases is
experiencing a renaissance—and initial results look promising.
While the field has seen a setback with the recent request for more
data by the FDA for the approval of MDMA for PTSD, research into
different psychedelic compounds continues, promising new hopes to
battle worldwide mental health crises. In the newest episode of the
BioRevolution podcast, Andreas Horchler and Louise von Stechow
discuss the history, the promise, and the risks of psychedelics as
treatments for psychiatric diseases with neuroscientist,
psychedelics expert, and executive coach Galyna Pidpruzhnykova
https://www.linkedin.com/in/galynapidpruzhnykova/
https://www.galynapipdpruzhnykova.com/ Galyna also outlines her
efforts to develop a psychedelics strategy to battle the mental
health crisis in Ukraine, where the Ministry of Health published a
draft law for research on psychedelic compounds just a few days
after we recorded this podcast.
https://www.linkedin.com/feed/update/urn:li:activity:7308180815761330176/
Disclaimer: Louise von Stechow & Andreas Horchler and their
guests express their personal opinions, which are founded on
research on the respective topics, but do not claim to give
medical, investment or even life advice in the podcast. Learn more
about the future of biotech in our podcasts and keynotes. Contact
us here: scientific communication: https://science-tales.com/
Podcasts: https://www.podcon.de/ Keynotes:
https://www.zukunftsinstitut.de/louise-von-stechow